Effects of SGLT2 Inhibitors on Hematologic Parameters in Patients with Type 2 Diabetes Mellitus: A Retrospective Study

Year 2024, Volume: 8 Issue: 2, 154 - 162, 30.08.2024

Baris Karagün , Okan Sefa Bakıner

Abstract

Aim: SGLT2 (Sodium-Glucose Cotransporter 2) inhibitors have demonstrated significant benefits in reducing cardiovascular events and improving renal outcomes in patients with type 2 diabetes mellitus (DM). However, their effects on hematopoiesis are not fully understood. This study aimed to investigate the impact of SGLT2 inhibitors on hematocrit, erythrocyte count levels, and various hematologic parameters in patients with type 2 DM

Methods: A total of 116 patients with type 2 DM using SGLT2 inhibitors were included in the study. Demographic and clinical characteristics, as well as laboratory parameters, were collected at baseline and during control examinations. The patients were stratified based on the specific SGLT2 inhibitor received (dapagliflozin or empagliflozin), and comparisons were made between baseline and control values.

Results: The study found a significant increase in hematocrit and erythrocyte count levels among patients using SGLT2 inhibitors compared to baseline values (p=0.002; p<0.001). This increase was more pronounced in patients treated with empagliflozin compared to dapagliflozin. Additionally, mean platelet volume (MPV) and red cell distribution width (RDW) values decreased following SGLT2 inhibitor use, potentially indicating favorable cardiovascular effects (p=0.038; p=0.005).

Conclusion: SGLT2 inhibitors exert significant effects on hematopoiesis, leading to increased hematocrit and erythrocyte count levels in patients with DM. These findings contribute to our understanding of the hematologic effects of SGLT2 inhibitors and highlight their potential benefits beyond glycemic control in patients with type 2 DM. Further research is warranted to elucidate the underlying mechanisms and clinical implications of these findings.

Keywords

Dapagliflozin, Erythrocytosis, Empagliflozin, Hematologic parameters

Tip 2 Diyabetli Hastalarda SGLT2 İnhibitörlerinin Hematolojik Parametreler Üzerindeki Etkileri: Retrospektif Bir Çalışma

Abstract

Amaç: SGLT2 (Sodyum-Glukoz Kotransporter 2) inhibitörleri, tip 2 diyabetes mellitus (DM) hastalarında kardiyovasküler olayları azaltmada ve böbrek sonuçlarını iyileştirmede önemli faydalar göstermiştir. Ancak, bu ilaçların hematopoez üzerindeki etkileri tam olarak anlaşılmamıştır. Bu çalışma, SGLT2 inhibitörlerinin tip 2 DM hastalarındaki hematokrit, eritrosit sayısı düzeyleri ve çeşitli hematolojik parametreler üzerindeki etkilerini araştırmayı amaçladı.

Gereç ve Yöntemler: Çalışmaya SGLT2 inhibitörleri kullanan toplam 116 tip 2 DM hastası dahil edilmiştir. Demografik ve klinik özellikler ile laboratuvar parametreleri, başlangıçta ve kontrol muayenelerinde toplanmıştır. Hastalar, aldıkları spesifik SGLT2 inhibitörüne (dapagliflozin veya empagliflozin) göre gruplandırılmış ve başlangıç ile kontrol değerleri arasında karşılaştırmalar yapılmıştır.

Sonuçlar: Çalışma, SGLT2 inhibitörleri kullanan hastalar arasında hematokrit ve eritrosit sayısı düzeylerinde başlangıç değerlerine kıyasla anlamlı bir artış olduğunu buldu (p=0.002; p<0.001). Bu artış, dapagliflozin ile tedavi edilen hastalara kıyasla empagliflozin ile tedavi edilen hastalarda daha belirgindi. Ayrıca, ortalama trombosit hacmi (MPV) ve kırmızı hücre dağılım genişliği (RDW) değerleri SGLT2 inhibitörü kullanımından sonra azaldı ve bu durum potansiyel olarak olumlu kardiyovasküler etkileri gösterebilir (p=0.038; p=0.005).

Sonuç: SGLT2 inhibitörleri, hematopoez üzerinde önemli etkiler göstererek DM hastalarında hematokrit ve eritrosit sayısı düzeylerinde artışa yol açar. Bu bulgular, SGLT2 inhibitörlerinin hematolojik etkilerini anlamamıza katkıda bulunur ve tip 2 DM hastalarında glisemik kontrolün ötesindeki potansiyel faydalarını vurgular. Bu bulguların altında yatan mekanizmaları ve klinik sonuçları açıklığa kavuşturmak için daha fazla araştırma gereklidir.

Keywords

Dapagliflozin, Eritrositoz, Empagliflozin, Hematolojik parametreler

References

• 1. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, vd. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol JASN. Ocak 2011;22(1):104-12.
• 2. DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. Ocak 2017;13(1):11-26.
• 3. Tang J, Ye L, Yan Q, Zhang X, Wang L. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism. Front Pharmacol. 23 Şubat 2022;13:800490.
• 4. Dekkers CCJ, Sjöström CD, Greasley PJ, Cain V, Boulton DW, Heerspink HJL. Effects of the sodium-glucose co-transporter- 2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21(12):2667-73.
• 5. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, vd. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Lond Engl. 05 Ocak 2019;393(10166):31-9.
• 6. Pozzi A, Cirelli C, Merlo A, Rea F, Scangiuzzi C, Tavano E, vd. Adverse effects of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: a systematic review and meta- analysis. Heart Fail Rev. 01 Ocak 2024;29(1):207-17.
• 7. Packer M. Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium-glucose cotransporter 2 inhibitors. Eur Heart J. 21 Aralık 2023;44(48):5027-35.
• 8. Scholtes RA, Muskiet MHA, van Baar MJB, Hesp AC, Greasley PJ, Karlsson C, vd. Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial. Diabetes Care. 2021;44(2):440-7.
• 9. Ekanayake P, Mudaliar S. Increase in hematocrit with SGLT- 2 inhibitors - Hemoconcentration from diuresis or increased erythropoiesis after amelioration of hypoxia? Diabetes Metab Syndr Clin Res Rev. 2023;17(2):102702.
• 10. Kocatepe K, Bayraktaroğlu T, Karagözoğlu1 K, Tekin S, Topaloğlu Ö. Tip 2 Diyabetiklerde Sodyum Glukoz Transporter 2 İnhibisyonu İle Ortaya Çikan Hemokonsantrasyon Ne Kadar Önemlidir?: Olgu Sunumu ve Literatürün Gözden Geçirilmesi. İçinde 2024. Erişim Adresi: Http://Www.Temhk.Org/
• 11. Dai ZC, Chen JX, Zou R, Liang XB, Tang JX, Yao CW. Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease. Front Immunol. 2023;14:1213473.
• 12. O’Neill J, Fasching A, Pihl L, Patinha D, Franzén S, Palm F. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol. 2015;309(3):F227-234.
• 13. Sano M, Goto S. Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects. Circulation. 2019;139(17):1985-7.
• 14. Mazer CD, Hare GMT, Connelly PW, Gilbert RE, Shehata N, Quan A, vd. Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation. 2020;141(8):704-7.
• 15. Gangat N, Szuber N, Alkhateeb H, Al-Kali A, Pardanani A, Tefferi A. JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy. Blood. 2021;138(26):2886-9.
• 16. Ghanim H, Abuaysheh S, Hejna J, Green K, Batra M, Makdissi A, Chaudhuri A, Dandona P. Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis. J Clin Endocrinol Metab. 2020;105(4):dgaa057.
• 17. Son M, Lee YS, Hong AR, Yoon JH, Kim HK, Kang HC, vd. Improved Erythrocyte Deformability Induced by Sodium- Glucose Cotransporter 2 Inhibitors in Type 2 Diabetic Patients. Cardiovasc Drugs Ther. Şubat 2022;36(1):59-67.
• 18. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28.
• 19. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357.
• 20. Heerspink Hiddo J.L., Stefánsson Bergur V., Correa-Rotter Ricardo, Chertow Glenn M., Greene Tom, Hou Fan-Fan, vd. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 07 Ekim 2020;383(15):1436-46.
• 21. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, vd. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 12 Ocak 2023;388(2):117-27.
• 22. Taşkaldıran I, Kuşkonmaz Ş, Çulha C. Use of Sodium Glucose Co-Transporter 2 Inhibitor (SGLT2i) in Geriatric Population. Türkiye Diyabet Ve Obezite Derg. 29 Ağustos 2021;5(2):158- 64.
• 23. Soyaltin UE, Çetinkalp Ş, Şimşir IY, Kandemir A, Seziş M. A Sweet Dream with SGLT2 Inhibitors. Türkiye Diyabet Ve Obezite Derg. 29 Ağustos 2021;5(2):237-40.
• 24. Kaneto H, Obata A, Kimura T, Shimoda M, Kinoshita T, Matsuoka T aki, vd. Unexpected Pleiotropic Effects of SGLT2 Inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class. Int J Mol Sci. Ocak 2021;22(6):3062.
• 25. Yaribeygi H, Maleki M, Nasimi F, Butler AE, Jamialahmadi T, Sahebkar A. Sodium-glucose co-transporter 2 inhibitors and hematopoiesis. J Cell Physiol. 2022;237(10):3778-87.
• 26. Heyman SN, Armaly Z, Hamo-Giladi DB, Abassi Z. Novel perspectives regarding the physiologic mechanisms by which gliflozins induce reticulocytosis and erythrocytosis. Am J Physiol Endocrinol Metab. 01 Kasım 2023;325(5):E621-3.
• 27. Gupta R, Gupta A, Shrikhande M, Tyagi K, Ghosh A, Misra A. Marked erythrocytosis during treatment with sodium glucose cotransporter-2 inhibitors-report of two cases. Diabetes Res Clin Pract. Nisan 2020;162:108127.
• 28. Wang X, Fu R, Liu H, Ma Y, Qiu X, Dong Z. The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials. Ann Palliat Med. Haziran 2021;10(6):6467- 81.
• 29. Korniluk A, Koper-Lenkiewicz OM, Kamińska J, Kemona H, Dymicka-Piekarska V. Mean Platelet Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions. Mediators Inflamm. 17 Nisan 2019;2019:1-14.
• 30. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, vd. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost JTH. Ocak 2010;8(1):148-56.
• 31. Danese E, Lippi G, Montagnana M. Red blood cell distribution width and cardiovascular diseases. J Thorac Dis. Ekim 2015;7(10):E402.
• 32. Symeonidis A, Kouraklis-Symeonidis A, Psiroyiannis A, Leotsinidis M, Kyriazopoulou V, Vassilakos P, vd. Inappropriately low erythropoietin response for the degree of anemia in patients with noninsulin-dependent diabetes mellitus. Ann Hematol. Şubat 2006;85(2):79-85.